Powles Trevor J
Parkside Oncology Centre, Parkside, Wimbledon, London SW19 5NB, UK.
Breast Cancer Res. 2006;8(5):111. doi: 10.1186/bcr1601.
Placebo controlled trials in over 25,000 women showed that tamoxifen reduced breast cancer risk by about 40% and osteoporotic fracture risk by about 32%. Similarly placebo controlled trials in nearly 18,000 women showed that raloxifene reduced breast cancer risk by 44-72% and osteoporotic fractures risk by 30-50%. A direct comparison of tamoxifen with raloxifene showed similar risk reduction for breast cancer and osteoporotic fractures with less toxicity for raloxifene.
超过25000名女性参与的安慰剂对照试验表明，他莫昔芬可将乳腺癌风险降低约40%，将骨质疏松性骨折风险降低约32%。同样，近18000名女性参与的安慰剂对照试验表明，雷洛昔芬可将乳腺癌风险降低44%-72%，将骨质疏松性骨折风险降低30%-50%。他莫昔芬与雷洛昔芬的直接对比显示，二者在降低乳腺癌和骨质疏松性骨折风险方面效果相似，但雷洛昔芬的毒性更小。
